Loteprednol etabonate mucosal penetrating particle: Phase II started

Kala began the single-masked, U.S. Phase II KPI-121-C-004 trial to evaluate 0.25% and 1% LE-MPP given 4 times daily in up to 20 patients with intraretinal or subretinal fluid secondary to DME or RVO. ...